Next generation sequencing NGS News and Research

RSS

GenomOncology collaborates with RPCI to develop informatics solution for Next Generation Sequencing

GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.

11 Feb 2014

Covaris introduces truXTRAC High Throughput FFPE DNA Extraction & Purification Kit at 2014 AGBT

Covaris, Inc. introduced the truXTRAC™ High Throughput FFPE DNA Extraction & Purification Kit at the 2014 Advances in Genome Biology and Technology (AGBT) meeting held in Marco Island, Florida.

11 Feb 2014

Rubicon Genomics introduces PicoPLEX DNA-seq Kits for use with Illumina NGS platforms

Rubicon Genomics, Inc. today announced the launch of its PicoPLEX DNA-seq Kits for use with Illumina next-generation sequencing (NGS) platforms. PicoPLEX's outstanding robustness and reproducibility have made it the worldwide standard for single-cell DNA amplification for microarray and PCR-based pre-implantation genetic screening and diagnosis. PicoPLEX DNA-seq now enables researchers and clinicians to access PicoPLEX technology for analyses conducted on Illumina NGS systems.

10 Feb 2014

Biotheranostics launches complete genomic tests for metastatic cancer patients

bioTheranostics, Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care.

4 Feb 2014

Thermo Fisher Scientific fourth quarter revenue increases 6% to $3.47 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2013.

30 Jan 2014

Scientists develop new genetic platform that yields novel antibiotic from ocean bacteria

Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound.

23 Jan 2014

Fluxion Biosciences announces release of IsoFlux Rare Cell Enrichment Kit

Fluxion Biosciences, Inc. announced the release of a new reagent kit for the IsoFlux System designed to provide more options for circulating tumor cell and other rare cell capture from biological samples. The IsoFlux Rare Cell Enrichment (Streptavidin) Kit incorporates streptavidin-coated magnetic beads that can bind with one or more biotinylated antibodies targeted towards cell-surface markers on the cells of interest.

From Fluxion Biosciences 21 Jan 2014

Illumina inks multi-year supply agreement with LabCorp

Illumina, Inc. today announced it has entered into a multi-year supply agreement with Laboratory Corporation of America Holdings. The agreement gives LabCorp expanded rights to use Illumina next-generation sequencing and microarray equipment and supplies to develop, validate and introduce laboratory-developed tests to clinicians in the United States and Canada.

From Illumina, Inc. 21 Jan 2014

New Microlab® NIMBUS® Select workstation with Ranger Technology launched by Hamilton Robotics and Coastal Genomics

At the annual Society for Laboratory Automation and Screening (SLAS) meeting Hamilton Robotics has announced a partnership with Coastal Genomics to launch the new Microlab® NIMBUS® Select workstation with Ranger Technology. The new automated workstation provides a faster and more economical automated solution to agarose gel selection of DNA fragments, generating high-quality material for downstream use in next-generation sequencing (NGS), cloning and gene synthesis applications.

20 Jan 2014

Sapio Sciences announces release of Exemplar NGS LIMS system

Sapio Sciences is pleased to announce the release of Exemplar NGS LIMS. Sapio's NGS LIMS system will track multiple next-generation sequencing platform workflows from request through processing and analysis.

20 Jan 2014

Life Technologies, Quest Diagnostics sign multi-year license and supply agreement

Life Technologies has completed a multi-year license and supply agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, that gives Quest rights to develop molecular tests on the Ion Torrent next-generation sequencing platform. Under the agreement, Quest may use the platform and related consumables to independently develop new tests for numerous areas of their business.

From Quest Diagnostics 10 Jan 2014

Illumina signs multi-year licensing agreement with Quest Diagnostics

Illumina, Inc. today announced it has entered into a multi-year licensing agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, related to the use of Illumina's next-generation sequencing technology for clinical laboratory testing.

From Illumina, Inc. 9 Jan 2014

Special publication details breakthrough research on causes of vascular disease

The world's leading voices in the fight against Pulmonary Hypertension have compiled a special publication detailing the breakthrough research into the causes of this debilitating vascular disease.

6 Jan 2014

Researchers identify two novel BRAF fusions in melanomas

Stand Up To Cancer, the charitable initiative supporting ground-breaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, announces that Jeffrey A. Sosman, M.D., a Stand Up To Cancer Melanoma Dream Team investigator, William Pao, M.D., Ph.D., a 2009 Stand Up To Cancer Innovative Research Grant recipient and colleagues identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets, and that melanomas with these fusions were found to be potentially sensitive to anticancer drugs called MEK inhibitors, according to a study recently published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

2 Jan 2014

Changes to LZTR1 gene predispose people to develop schwannomas

Changes to a gene called LZTR1 predispose people to develop a rare disorder where multiple tumors called schwannomas form near nerve pathways, according to a study published today in the journal Nature Genetics and led by researchers from the University of Alabama at Birmingham.

24 Dec 2013

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hematologic malignancies, FoundationOne Heme, identified both novel and previously reported clinically actionable genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander Lesokhin, M.D., medical oncologist, Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology Annual Meeting in New Orleans.

10 Dec 2013

New research project to genetically discriminate "identical" monozygotic twins

Eurofins Scientific, a European leader in Genomics Services, Forensics and Paternity Testing, announces a milestone in genetic and forensic research.

10 Dec 2013

Update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation procedures

Uroplasty, Inc. a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation (PTNS) procedures delivered via the Company's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.

4 Dec 2013

New whitepaper examines main strategies employed to optimise target enrichment for NGS assays

Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a free whitepaper titled ‘The importance of enrichment assay choice and optimisation for confident variant detection.’ The paper investigates the main strategies employed to optimise target enrichment for next generation sequencing assays, assisting researchers to make informed decisions when designing studies.

From Oxford Gene Technology 30 Nov 2013

Fluxion Biosciences reports first study results from early stage NSCLC patients

Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn's lab at Stanford University. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.

From Fluxion Biosciences 27 Nov 2013